Download Drug Discovery for Treatment of Post-Traumatic Alzheimer’s and Chronic Traumatic Encephalopathy (CTE)

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Neuropharmacology wikipedia , lookup

Blood–brain barrier wikipedia , lookup

Neuropsychopharmacology wikipedia , lookup

Transcript
Drug Discovery for Treatment of
Post-Traumatic Alzheimer’s and
Chronic Traumatic Encephalopathy (CTE)
Sam Gandy, M.D., Ph.D.
Director, NFL Neurological Center
Mount Sinai School of Medicine
James J Peters VA Medical Center
Steven T. DeKosky, M.D.
Vice President and Dean
University of Virginia School of Medicine
Military Health System Research Symposium
August 16, 2012
The Post-Traumatic Alzheimer’s-CTE Spectrum
How can our current understanding of Alzheimer’s
be applied to experimental therapeutics of
post-traumatic Alzheimer’s disease and CTE?
A major limiting factor in sporadic AD is believed to
be the difficulty in determining when the long presymptomatic and prodromal periods begin prior to
cognitive decline.
With post-traumatic Alzheimer’s and/or CTE,
we may have the benefit of knowing the earliest
point of initiation; i.e., the timing of the TBI(s).
Neurodegeneration Keywords
•
•
•
•
•
•
•
•
•
Amyloid-beta peptide
Normal metabolic peptide
Amyloid oligomers
Pathological floating clumps
Amyloid deposits
Pathological precipitate
Amyloid plaques
Pathological deposit with
core and corona
Amyloid angiopathy
Pathological vessel amyloid
Tau
Cytoskeletal protein
Tauopathy
Tau deposits inside cells
Neurofibrillary tangles
Spindle shaped tau deposit
Conventional Alzheimer pathway
TBI
AbetaA42
tauopathy
accumulation
neurodegeneration
Possible pathways from TBI to AD or CTE
TBI
Abeta42
tauopathy
neurodegeneration
APOE epsilon 4 carriers are especially prone to
develop Alzheimer’s and CTE
Mauri M, Sinforiani E, Bono G, Cittadella R, Quattrone A, Boller F, Nappi G. Interaction
between Apolipoprotein epsilon 4 and traumatic brain injury in patients with Alzheimer's
disease and Mild Cognitive Impairment. Funct Neurol. 2006 Oct-Dec;21(4):223-8.
Luukinen H, Viramo P, Herala M, Kervinen K, Kesäniemi YA, Savola O, Winqvist S,
Jokelainen J, Hillbom M. Fall-related brain injuries and the risk of dementia in elderly
people: a population-based study. Eur J Neurol. 2005 Feb;12(2):86-92.
Sabo T, Lomnitski L, Nyska A, Beni S, Maronpot RR, Shohami E, Roses AD, Michaelson
DM. Susceptibility of transgenic mice expressing human apolipoprotein E to closed head
injury: the allele E3 is neuroprotective whereas E4 increases fatalities. Neuroscience.
2000;101:879-84.
Han SH, Chung SY. Marked hippocampal neuronal damage without motor deficits after
mild concussive-like brain injury in apoE-deficient mice. Ann N Y Acad Sci. 2000;903:35765. .
Mayeux R, Ottman R, Maestre G, Ngai C, Tang MX, Ginsberg H, Chun M, Tycko B,
Shelanski M. Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in
patients with Alzheimer's disease. Neurology. 1995 Mar;45(3 Pt 1):555-7.
Baseline
78 wks Bapineuzumab Rx
Autophagy (“self-eating”) is a normal cellular garbage disposal system.
Lysosomes and vacuoles totally surround debris and attempt to digest it.
Inadequate autophagy may underlie some neurodegenerative pathology.
A major autophagy pathway is triggered by nutrient deprivation and acts
via mTOR.
Latrepirdine improves behavior and arrests
progression of molecular neuropathology
while activating autophagy in TgCRND8
mice
Latrepirdine activates autophagy
as indicated by changes in p62, LC3-I, LC3-II
Latrepirdine activates
autophagy and
stimulates
neurogenesis
Current evidence suggests that pro-neurogenic
interventions improve outcome from experimental TBI
Han X, Tong J, Zhang J, Farahvar A, Wang E, Yang J, Samadani U, Smith DH,
Huang JH. Imipramine treatment improves cognitive outcome associated with
enhanced hippocampal neurogenesis after traumatic brain injury in mice. J
Neurotrauma. 2011 Jun;28(6):995-1007.
Blaiss CA, Yu TS, Zhang G, Chen J, Dimchev G, Parada LF, Powell CM, Kernie SG.
Temporally specified genetic ablation of neurogenesis impairs cognitive recovery after
traumatic brain injury. J Neurosci. 2011 Mar 30;31(13):4906-16.
Barha CK, Ishrat T, Epp JR, Galea LA, Stein DG. Progesterone treatment normalizes
the levels of cell proliferation and cell death in the dentate gyrus of the hippocampus
after traumatic brain injury. Exp Neurol. 2011 Sep;231(1):72-81.
Bregy A, Nixon R, Lotocki G, Alonso OF, Atkins CM, Tsoulfas P, Bramlett HM, Dietrich
WD. Posttraumatic hypothermia increases doublecortin expressing neurons in the
dentate gyrus after traumatic brain injury in the rat. Exp Neurol. 2012 Feb;233(2):8218.
Which signaling pathways are important in
regulating Abeta42 metabolism at the synapse?
DCG-IV stimulates
generation of Abeta42
but not Abeta40
Pretreatment with
mGluR2/3 antagonist blocks
DCG-IV stimulated
generation of Abeta42
The mGluR2/3 antagonist
BCI-838 reduces amyloid
oligomer accumulation and
improves behavior in APP
transgenic mice
APP transgenic mice show
impaired neurogenesis, that is
corrected by BCI-838
Latrepirdine
and
BCI-838
are being tested
in the
Ahlers
blast model of
mTBI that causes
chronic PTSD
phenotype
Summary
1. An important issue for clarification in understanding link
between post-traumatic AD and CTE is the role of Abeta in
the induction and pathogenesis of the tauopathy of CTE.
2. Pro-autophagic compounds such as latrepirdine may help
the brain to prevent or clear neurodegenerative pathology.
3. Pro-neurogenic compounds such as latrepirdine and BCI838 may be useful in preventing or in helping the brain
recover from late neurodegenerative sequelae of TBI and
CTE.
4. Next steps will be testing each drug, and combination of
both, in the Ahlers blast model.